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Abstract: In men, prostate cancer is one of the most common cancers worldwide and the 
second leading cause of death among all cancer types in Europe and North America, with the 
numbers of those affected continuing to increase. Recent studies have identified a recurrent 
fusion of TMPRSS2 with members of the ETS family of transcription factors in about 80% of 
prostate cancer tissues. Among them, the TMPRSS2-ERG fusion accounts for approximately 
50% of these cases. TMPRSS2 is highly regulated by androgen receptor and the chromosomal 
rearrangement abnormally induces ERG production by androgen. To investigate the effects of 
ERG overexpression on its target genes expression and prostate cancer development, plasmids 
were first constructed by inserting the truncated ERG into an expression vector in the forward or 
reverse directions. A predicted three-dimensional model of the protein structure of the truncated 
ERG, along with immunofluorescence assays, suggest that the minor deletion on the N-terminus 
does not appear to affect the structure or function of ERG. Results from ERG target gene 
expression profile indicate that TMPRSS2-ERG fusion-induced aberrant ERG overexpression 
is likely involved in prostate cancer development by enhancing tumor angiogenesis.
Keywords: prostate cancer, androgen receptor, TMPRSS2, ERG, chromosomal translocation
Introduction
Prostate cancer is one of the most prevalent threats to men’s health in the Western 
world and it accounts for the second largest number of male cancer deaths in the 
United States.1–5 It is understood to be a disease of complex and multifactorial origins. 
It appears that race, family history, and age are major factors related to its incidence. 
Men who have first-degree relatives with prostate cancer are at increased risk for 
the disease, with the risk of developing prostate cancer increasing with the number 
of relatives diagnosed.6 Males under the age of 50 have low rates of occurrence. 
However, rates increase rapidly after the age of 50 years, with 73 years being the 
average age at time of diagnosis.2,7 Because of improvements in the standards of 
modern living and advances in medicine, life expectancy has progressively increased 
and as a result, prostate cancer incidences are expected to increase proportionally. 
Hormone therapy benefits about 80% of prostate cancer patients by retarding the 
progression of the disease.8 However, prostate cancer in the majority of the patients 
who initially benefited from hormonal therapy will eventually develop into an 
aggressive, hormone-independent form, with little hope for further intervention.9 
Despite the high prevalence of prostate cancer, knowledge about the molecular and 
cellular mechanisms that underlie the cause of the disease is limited, and no cure yet 
exists for late stage prostate cancer.
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The recently identified high incidence recurrent fusion of 
TMPRSS2 with members of the E26 transformation-specific 
(ETS) family of transcription factors, including ERG, ETV1, 
ETV4, and ETV5, in prostate cancer samples has opened a new 
field in prostate cancer research.10–12 This is significant not 
only for understanding the underlying molecular mechanisms 
of prostate cancer development, but also for designing 
strategies for diagnosis, prognosis, and the differential 
treatment of prostate cancer.10,13,14 About 80% of prostate 
tumors contain genomic fusions of TMPRSS2 and members 
of the ETS family of transcription factors. Of these, ∼50% 
contains TMPRSS2-ERG fusions.15,16 Furthermore, it has been 
reported that TMPRSS2-ERG-positive prostate cancers have 
more aggressive phenotypes than those of TMPRSS2-ERG-
negative cancers.17,18 Consequently, both short-term and 
long-term survival rates of patients with such fusions are 
significantly affected.19 Screening of prostate cancer samples 
found that among the 27 ETS factors, ERG is the most 
frequently overexpressed.20 The TMPRSS2 gene is located 
on chromosome 21 at 21q22.3 (Figure 1A) and encodes for 
a type II transmembrane serine protease.21 Normal prostate 
cells express little to no detectable TMPRSS2 protein, but 
high levels of TMPRSS2 protein have been found in a 
large percentage of prostate cancer cells.22 A recent study 
has demonstrated that the full-length TMPRSS2 protein 
is expressed in LNCaP cells, an androgen-responsive 
prostate cancer cell line, but is not detected in the androgen-
unresponsive prostate cancer cells PC-3 and DU-145.21 The 
expression of TMPRSS2 quickly increases in LNCaP cells 
after exposure to androgenic hormones indicating that it is 
likely a primary androgen receptor (AR) target gene.21 In fact, 
the TMPRSS2 promoter region has a 15-bp sequence that 
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Figure 1 chromosomal deletion and TMPRSS2-ERG fusion. A) Ideogram of chromosomal 21. B) Interstitial deletion and formation of the TMPRss2-eRg fusion. C) schematic 
illustration of the exons and gene sequences in the TMPRSS2-ERG gene fusion.  The gray box represents the open reading frame of TMPRSS2 while the striped box represents 
the open reading frame of ERG. each exon is indicated by numbers in the boxes and the numbers above the boxes are the last base of each exon. sequences at the fusion 
junction are indicated and the sequence from TMPRSS2 is underlined.
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contains a consensus AR-responsive element (ARE) which is 
likely involved in AR-ARE interaction and in the regulation 
of TMPRSS2 expression.23 Previous experiments have also 
suggested that the androgen-responsive promoter elements 
of TMPRSS2 are implicated in prostate cancer through the 
overexpression of members of the E26 transformation-
specific (ETS) family.19
One effect of the interstitial 3 Mb deletion from chromo-
somal region 21q22 is the generation of the TMPRSS2-ERG 
fusion gene, which contains the promoter/enhancer region 
of the TMPRSS2 gene and a part of the open reading frame 
of the ERG gene (Figure 1B). There are at least 17 distinct 
TMPRSS2-ERG transcripts generated from fusions between 
exons 1, 2, and 3 of TMPRSS2 and exons 2, 3, 4, 5, or 6 of 
ERG which have been identified,24 with the most commonly 
identified fusion in prostate cancer containing the promoter/
enhancer region and first exon of TMPRSS2 gene and exon 4 of 
ERG gene (Figure 1C). ERG is known to be a pivotal transcrip-
tion factor in cell differentiation and growth control pathways, 
and there are lines of evidence to suggest that overexpression 
of ERG may be involved in different stage of prostate cancer 
development.13,14,16,25 However, the molecular mechanisms 
underlying the chromosomal translocation and prostate cancer 
development are not known.20 We hypothesize that overexpres-
sion of the ETS factors resulting from TMPRSS2-ETS fusion 
plays an essential role in prostate cancer development, and 
the data from our research suggest that overexpression of the 
truncated ERG may affect prostate cancer development, most 
likely through enhancing angiogenesis.
Materials and methods
construction of overexpression 
vector, Psg5-eRg
Total RNA was purified from the VCaP prostate cancer 
cell line using an RNAqueous-4PCR kit (Ambion, Inc., 
Austin, TX). For cDNA synthesis, 5 µg of total RNA was 
reverse transcribed using random primers (Stratagene, La 
Jolla, CA) and SuperScript II reverse transcriptase (Invitrogen, 
Carlsbad, CA). The truncated open reading frame (ORF) of 
ERG was amplified by PCR using the following primers: 
Upper primer, 5′-ATGACCGCGTCCTCCTCCAGCGA-3′; 
Lower primer, 5′-TTAGTAGTAAGTGCCCAGATGAG-3′. 
XhoI and NheI restriction enzyme sites were added to the 
upper and lower primer ends, respectively. The full length of 
the ORF in the fusion gene was approximately 1.2 kb, and 
the amplified PCR product was purified with a Qiagen Gel 
Extraction kit (Qiagen, Inc., Valencia, CA). The PCR product 
was cloned into a TOPO-TA vector (Invitrogen). ERG was 
then sub-cloned into the PSG5 expression vector (J. Wong lab, 
Baylor College of Medicine, Houston, TX) on the XhoI site 
using T4 DNA ligase (Promega, Madison, WI). A negative 
control was constructed with the insert oriented in the 
opposite direction. Orientations were determined by digesting 
with NheI (Promega). DNA sequence and cloning junction 
were verified by sequencing (University of Pennsylvania 
DNA Sequencing Facility, Philadelphia, PA).
Cell culture and transient 
transfection
HeLa cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) (Cellgro, Mediatech, Inc., Herndon, VA) 
containing 10% fetal bovine serum (FBS) (Atlanta Biologicals, 
Lawrenceville, GA) and 1% antibiotics/antimycotics 
(Abx/Amx) (Gibco, Carlsbad, CA). NIH 3T3 cells were 
maintained in DMEM (Cellgro, Mediatech, Inc.) containing 
10% bovine calf serum (BCS) (Atlanta Biologicals, 
Lawrenceville, GA) and 1% Abx/Amx (Gibco). Cells were 
incubated at 37 °C and 4.7% CO
2
. HeLa and NIH 3T3 cells 
were transfected with plasmids containing either the forward 
insert or the reverse insert, using lipofectamine and PLUS 
reagent (Invitrogen). Cells were incubated in reduced serum 
opti-modified Eagle’s medium (Opti-MEM) (Gibco) for six 
hours. After this six-hour incubation, DMEM containing 1% 
Abx/Amx and either 10% FBS or 10% BCS was added to the 
HeLa and NIH 3T3 cells, respectively. Cells were incubated 
for an additional 36 hours at 37 °C and 4.7% CO
2
.
Lysis and western blotting
Cells were collected and lysed with EBC buffer containing 
20 mM Tris HCl (pH 8.0), 125 mM EDTA, and 0.5% NP-40. 
Protein samples were separated by SDS-PAGE electrophoresis 
and transferred to a nitrocellulose membrane. All membranes 
were stained with Ponceau S Solution to confirm successful 
transfer of the proteins (Sigma-Aldrich, St. Louis, MO). 
They were then blocked with 5% milk in TBST (Tris-base, 
NaCl, and 1% Tween 20, pH 7.6). Proteins were incubated 
in 2.5% milk in TBST with ERG-1/2/3 rabbit polyclonal IgG 
(0.2 µg/mL) (Santa Cruz Biotechnology, Santa Cruz, CA) as 
a primary antibody and donkey-anti-rabbit IgG (0.08 µg/mL) 
(Pierce Biotechnology, Rockford, IL) as a secondary antibody. 
The blot was stripped and reprobed by anti-actin (1 µg/mL) 
(Calbiochem, San Diego, CA) and peroxidase goat anti-
mouse IgM (0.01 µg/mL) (Calbiochem). The blots were 
detected using the Super Signal West Pico Chemiluminescent 
Substrate detection system (Pierce Biotechnology).
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Immunofluorescence
After transfection and incubation on glass coverslides for 
24 hours at 37 °C and 4.7% CO
2
, HeLa cells were washed 
once with 1X phosphate-buffered solution (PBS), fixed with 
Cytofix/Cytoperm (BD Biosciences, San Diego, CA), and 
blocked for 30 minutes with 1X Perm/Wash (BD Biosciences). 
Cells were incubated with primary and secondary antibodies 
in 1X Perm/Wash at 37 °C for one hour each. ERG-1/2/3 
rabbit polyclonal IgG (Santa Cruz Biotechnology) was 
used as a primary antibody (0.2 µg/mL), Alexa Fluor 
488 donkey anti-rabbit IgG was used as a secondary 
antibody (0.2 µg/mL; Molecular Probes, Eugene, OR), and 
bis-benzamide (1 µg/mL, Sigma-Aldrich) was used to stain 
the nucleus. Coverslips were mounted on glass slides using 
aqueous mounting media containing anti-fading reagent 
(Biomeda Corp., Foster City, CA). Slides were examined 
with the use of a Nikon Eclipse E800 microscope. Z-stack 
images were obtained using an RT Slider Spot camera 
(Diagnostic Instruments, Inc., Sterling Heights, MI) and 
analyzed with Image-Pro Plus, Version 6.2.0.424 (Media 
Cybernetics, Bethesda, MD) and Autoquant X, Version 
X2.0.0 (Media Cybernetics) softwares.
Bioinformatic prediction 
of three-dimensional structures
Three-dimensional structures corresponding to sequences of 
the full-length ERG, the truncated ERG, and the functional 
domains were predicted by using bioinformatic softwares. 
The MUSTER database was used to generate the three-
dimensional models of the proteins,26 Jmol was used for 
visualization (www.jmol.org), and PFAM was used for the 
domain search.27
Analysis of eRg target genes
Total RNA was purified from transiently transfected HeLa 
or NIH 3T3 cells using an RNAqueous-4PCR kit (Ambion, 
Austin, TX). For cDNA synthesis, 5 µg of total RNA was 
reverse transcribed using random primers (Stratagene, 
La Jolla, CA) and Superscript II reverse transcriptase 
(Invitrogen). ERG target genes were detected by PCR 
using the specifically-designed primers (Invitrogen). The 
following PCR conditions were used routinely in a Genius 
thermal cycler (Techne Inc., Burlington, NJ): one cycle, 
95 °C, two minutes; 35 cycles, 95 °C, one minute, 60 °C, 
one minute, 72 °C, one minute; one cycle, 72 °C, five 
minutes. PCR products were analyzed on a 1% agarose gel 
and visualized with ultraviolet light. The amplified bands 
were quantified using Image-J software.
Results and discussion
cloning and overexpression 
of the truncated eRg
The TMPRSS2-ERG gene fusion is heterogeneously expressed 
due to a variety of interstitial deletions, creating at least 
17 distinct transcripts depending on the location of the fusion. 
Alternative splicing can cause fusions that occur between 
exons 1, 2, or 3 of TMPRSS2 and exons 2, 3, 4, 5, or 6 of 
ERG. The most common TMPRSS2-ERG fusion occurs 
between exon 1 of TMPRSS2 and exon 4 of ERG (Figure 1C). 
In this fusion gene, the native ATG is lost and translation is 
assumed to start from the first ATG. The truncated open read-
ing frame (ORF) was amplified from VCaP prostate cancer 
cells and was bidirectionally cloned into expression vector 
PSG5 as described in Materials and methods (Figure 2A). 
As expected, for successful ligations between ERG and 
PSG5, XhoI digests of the clones show two distinct bands, 
corresponding to the 4.5 kb vector and the 1.5 kb insert 
(Figure 2B, lanes 1 and 2). Upon separate digestion with 
NheI, plasmids with the insert oriented in the forward direc-
tion have one large fragment of approximately 6 kb and a 
small undetectable fragment of less than 20 bp, which is not 
detectable on the agarose gel (Figure 2B, lane 3). In contrast, 
plasmids with the insert cloned in the reverse direction should 
contain fragments of 4.5 kb and 1.5 kb, which are of similar 
size to digestion with XhoI (Figure 2B, lane 4). These DNA 
sequences and orientations were verified by sequencing. 
Because of their size, plasmids containing the reverse insert 
served as an ideal negative control in future experiments. The 
overexpression of the truncated ERG was shown by western 
blotting (Figure 2C). The molecular weight of the full-length 
ERG has been estimated to be 49 kD. With the deletion of 
31 amino acids from the N-terminus, the truncated ERG is 
expected to be approximately 45 kD. Figure 2C shows that 
after 36 hours of transient transfection with PSG5-ERG, both 
NIH3T3 and HeLa cell lines overexpress a protein of approxi-
mately 45 kD. In contrast, cells transfected with no DNA or 
with the vector containing a reverse ERG insert exhibit no 
bands. This indicates that the truncated ERG was successfully 
cloned and overexpressed in both cells. During the preparation 
of this manuscript, a published paper verified that the truncated 
ERG from the TMPRSS2-ERG fusion is indeed translated with 
the first ATG as an alternative translation initiation site.15
Predicted three-dimensional  
structure of the truncated eRg
The ERG used in these experiments is modeled after the 
most common TMPRSS2-ERG fusion which occurs between 
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exon 1 of TMPRSS2 and exon 4 of ERG. The use of an 
alternate ATG start codon generates a truncated ERG, which 
deletes 31 amino acids from the N-terminus of the protein. 
However, this truncation does not affect the DNA binding 
domain (ETS) or the integrity of the pointed domain (PTN, 
Figure 3A), which is particularly important for both dimer-
ization and recruitment of other transcriptional factors.28 
To determine if the truncation of ERG affects the structure of 
the protein, we analyzed sequences of both the full-length and 
truncated ERG with bioinformatic softwares. The predicted 
three-dimensional structure of the truncated ERG appears to 
be very similar to that of the full-length protein. Both visibly 
contain five alpha helices (colored in pink) and multiple beta 
sheets (shown in yellow, Figure 3B). Although the software 
C
B Xhol Nhel
NIH3T3 HeLa
tERG
Actin
C CR RF F
1 2 3 4
1.5 kb
4.5 kb
A
(Reverse) (Forward)
XholXhol Xhol
Xhol Xhol
XholXhol
Xhol
Nhel
Nhel
Nhel
Nhel
Nhel
Nhel
ERG−1.5 kb
PSG5−4.5 kb
Figure 2 cloning and overexpression of truncated eRg. A) schematic strategy in cloning of the truncated eRg into the expression vector Psg5. B) Verification of the 
insertion by enzyme digestion restriction. Lanes 1 and 3:  Forward clone; and lanes 2 and 4: Reverse clone. C) Overexpression of truncated eRg. C: transfection with no DnA; 
F: transfected with Forward clone; and R: transfected with Reverse clone. teRg: truncated eRg.  The actin serves as internal control.
B
A
ADT1 ADT2PNT ETS
tERGERG
Jmol Jmol
Figure 3 schematic drawing of the truncated eRg protein A) and modeled three-dimensional protein structure B) of the truncated eRg. The activation domains,  ADT1 and 
ADT2, are located in the n- and c-termini, respectively. PnT represents the pointed domain and eTs represents the eTs-binding site.  The gray box depicts the 31 amino 
acid deletion from the n-terminus. Predicted three-dimensional models of the protein structures of the full-length eRg and truncated eRg show that the overall structure 
of the truncated eRg appears to be similar to that of the full length.  The alpha helices are shown in pink and the beta sheets were in yellow.
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has limited capabilities and could not specifically identify the 
location of the deletion, the overall structures of the native 
ERG and the truncated ERG are similar. This suggests that 
the small truncation in the ORF of ERG does not affect the 
overall protein structure significantly.
Overexpressed truncated eRg  
protein localizes to the nucleus
Since ERG is a transcription factor that binds to the promoter 
regions of target genes, its function depends on its ability 
to locate to the nucleus. The nuclear translocation signal 
sequence has not been identified for ERG. We cannot 
completely exclude the possibility that it is located in the 
deleted N-terminus. Therefore, it is important to verify that 
the nucleus translocation is not affected by the deletion. 
Immunofluorescent microscopy was performed on HeLa 
cells transiently transfected with no ERG or with plasmids 
containing either the forward or reverse ERG insert. Three-
dimensional images show that cells transfected with the 
forward insert exhibit intense green staining intermingled 
with blue nuclear staining, signifying that the protein is 
not simply residing in cytosolic areas around the nucleus 
(Figure 4, middle panel). This indicates that the truncated 
ERG is located in the nucleus. Control cells transfected 
with no ERG (Figure 4, left panel) or with the reverse 
insert (Figure 4, right panel) do not express ERG in their 
nuclei, as evidenced by the lack of green staining. Since 
cells transfected with PSG5-ERG demonstrate no signs of 
impaired ERG nuclear localization, this suggests that the 
small truncation in the ERG does not have a significant effect 
on subcellular location.
Overexpression of truncated eRg 
and regulation of target gene expression
Although the cellular functions of ERG have been 
established, the genes as well as the genetic pathways 
regulated by the TMPRSS2-ERG gene fusion product have 
not been characterized. However, because ERG is a pivotal 
transcription factor, it is reasonable to speculate that its 
actions are mediated through the regulation of its target genes. 
It is expected that the TMPRSS2-ERG gene fusion will first 
induce ERG overexpression and the overexpressed ERG will 
No DNA Forward Reverse
Figure 4 eRg is expressed in nuclei of cells transfected with PSG5-ERG. heLa cells transfected with plasmids containing the forward insert, the reverse insert, or no DnA were 
fixed, permeabilized, and stained for ERG (Green) using ERG-1/2/3 rabbit polyclonal IgG as the primary antibody and Alexa Fluor 488 donkey anti-rabbit IgG as the secondary 
antibody. Bis-benzamide (Blue) was used for nuclear staining. Images are taken with a 60X objective.  The top and bottom panels are top- and side-views, respectively.
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then affect the expression of its target genes either through 
activation or repression. Ultimately, it is the combinations 
of the target gene products that will lead to prostate cancer 
development. Previous literature has found that there is a 
wide variety of target genes that are up- or downregulated 
by ERG. Through comparison of the ERG-positive and 
ERG-negative prostate cancers, Iljin and colleagues identi-
fied a wide array of genes up- or downregulated by ERG.20 
Based on the microarray data, a broad screening of seven 
ERG target genes was first conducted by reverse transcrip-
tase-polymerase chain reaction (RT-PCR) using specifically 
designed primers (Table 1). It was initially determined that 
three genes, AGT, GPR116, KHDRBS3, appear to be upregu-
lated, whilst the RAMP1 is downregulated in certain degrees 
by ERG overexpression in both HeLa and NIH3T3 cells. Our 
results are consistent with the previous findings.20 However, 
the AGT appears to be affected the most. Figure 5 showed 
that the mRNA level of AGT is significantly upregulated in 
cells transfected with the forward insert. In contrast, cells 
transfected with the reverse insert do not exhibit this effect 
and express levels comparable to those of control cells 
transfected with no DNA. GAPDH, a housekeeping protein, 
was used as a loading control.
We speculate that aberrant expression of the truncated 
ERG could enhance prostate cancer angiogenesis through 
upregulating AGT expression. The human AGT gene, located 
on chromosome 1, consists of 5 exons and 4 introns and 
encodes for angiotensinogen. Angiotensinogen (AGT) is a 
452-amino acid glycoprotein that is synthesized and secreted 
mainly by the liver, but also by the brain.29,30 So far, it is 
the only known precursor of angiotensin I (Agt I), which 
is produced when AGT is cleaved by renin, an enzyme 
secreted by the kidneys. Agt I is a decapeptide which remains 
inactive, with no known function except to be converted 
by angiotensin-converting enzyme (ACE) into its active 
form, angiotensin II (Agt II). Agt II plays a major role in 
the renin-angiotensin system (RAS) and acts as a hormone 
through its interactions with its specific angiotensin receptors, 
AT
1
 and AT
2
.31 Renin, AGT, ACE, Agt II, and the angiotensin 
receptors have been found in the human prostate, prostate 
cancer cell lines, and rat prostatic cells.32,33 The presence of 
Agt II has been observed in basal cells of the normal prostate, 
as well as in proliferating neoplastic cells in high grade 
prostatic intraepithelial neoplasia and malignant prostate 
cancer cells.34,35 Agt II has been shown to increase the rate of 
proliferation of prostate cancer cells and it may act as an early 
marker of malignancy.32,33,35 It has been suggested that Agt II 
is a cell proliferative factor due to the fact that blocking its 
receptors has been shown to have anti-proliferative activity, 
as well as roles in decreasing prostate-specific antigen and 
improving the statuses of patients with hormone-refractory 
prostate cancer.34,35 Other research has provided evidence that 
Agt II induces oxidative stress, which may lead to prostate 
cancer.36 Chronic inflammation has long been associated 
with the development of cancer, by releasing reactive oxygen 
species that cause permanent DNA damage and genomic 
alterations, particularly in proliferating epithelium.37–39 
Agt II is involved in a variety of signaling pathways and 
Table 1 Primers used in reverse transcriptase-polymerase chain reaction
Name of the genes Abbreviations Primer sequences
Angiotensinogen AgT Upper: 5′-cTcTcTggAcTTcAcAgAAcTggA-3′  
Lower: 5′-gggAgTTTTgcTggAAAgTgAgAc-3′
ca2+-dependent secretion activator cADPs Upper: 5′-TAcTATcTTggAAggAgTgcTggc-3′  
Lower: 5′-TTcAcTcAcTgATgcTgTggcTTc-3′
ca2+-dependent activator protein  
for secretion 2
cADPs2 Upper: 5′-cAgTgAcgATgAAcAAgAccgcAT-3′  
Lower: 5′-AcTccATTTcgggcgcAATAcTc-3′
g protein-coupled receptor 116 gPR116 Upper: 5′-gggAgTggAATggAAccTATcAcT-3′  
Lower: 5′-ggcATgTgATgTTTTccccAggAA-3′
Kh domain containing, binding,  
signal transduction associated 3
KhDRBs3 Upper: 5′-cTgcgccTggTgAAccAAgAAATA-3′ 
Lower: 5′- ATAAgcTTcTgcAggTggggcAAA-3′
Phospholipase A2, group  VII  
(platelet-activating factor  
acetylhydrolase, plasma)
2g7 Upper: 5′-AAgTAcTgATggcTgcTgcAAgcT-3′  
Lower: 5′-cATgAgATgccAggTcAATgccAA-3′
Receptor activity modifying  
protein 1
RAMP1 Upper: 5′-ATcAccTcTTcATgAccAcTgcc-3′  
Lower: 5′-TAcAcAATgcccTcAgTgcgcTT-3′
glyceraldehyde-3-phosphate  
dehydrogenase (control)
gAPDh Upper: 5′-AcAgccTcAAgATcATcAgcAA-3′  
Lower: 5′-AccAcTgAcAcgTTggcAgT-3′
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it has been shown to stimulate the production of reactive 
oxygen species by upregulating NAD+/NADP+ (NADPH) 
oxidases.34,35 Additional studies have demonstrated that 
there are increased levels of reactive oxygen species-related 
enzymes and hydrogen peroxide in prostatic epithelial 
neoplasia and cancer.40
In summary, we have successfully cloned and overex-
pressed the truncated ERG corresponding to the product 
of TMPRSS2-ERG fusion in both NIH3T3 and HeLa 
cells. Three dimensional modeling shows that the small 
N-terminus deletion has little effect in the overall structure. 
Immunostaining demonstrated that the overexpressed 
truncated ERG takes a nuclear location. More importantly, 
overexpression of truncated ERG leads to the upregulation 
of its target gene AGT. Lines of evidence from previous 
research suggest that AGT plays some roles in prostate cancer 
development. We speculate that one of the mechanisms for 
the overexpression of the truncated ERG from TMPRSS2-
ERG fusion is enhancing angiogenesis through upregulation 
of angiotensinogen.
Acknowledgments
The authors want to thank Dr Jiemin Wong (Baylor College 
of Medicine, Houston, TX) for his kindness in offering the 
PAS-enhance-Luc reporter and the pOZ-N vector. We are 
grateful to Dr Ruth Borghaei (Philadelphia College of 
Osteopathic Medicine, Philadelphia, PA, USA) for her 
critical reading of the manuscript and valuable sugges-
tions. This work is supported partially by 2006 Formula 
Grant from Pennsylvania Department of Health, Bureau 
of Health Statistics and Research; partially by Center 
for Chronic Disorders of Aging, Philadelphia College 
of Osteopathic Medicine, Philadelphia, PA, USA, and 
partially by the Christian R. Mary F. Lindback Foundation, 
Philadelphia, PA. USA. The authors report no conflicts of 
interest in this work.
References
 1. Vindrieux D, Escobar P, Lazennec G. Emerging roles of chemokines 
in prostate cancer. Endocr Relat Cancer. 2009;16(3):663–673.
 2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 
2001. CA Cancer J Clin. 2001;51(1):15–36.
 3. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer 
J Clin. 2005;55(1):10–30.
 4. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer 
J Clin. 2004;54(1):8–29.
 5. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions 
in prostate cancer. Nat Rev Cancer. 2008;8(7):497–511.
 6. Johns LE, Houlston RS. A systematic review and meta-analysis of 
familial prostate cancer risk. BJU Int. 2003;91(9):789–794.
 7. Harden J. Developmental life stage and couples’ experiences with 
prostate cancer: a review of the literature. Cancer Nurs. 2005;28(2): 
85–98.
 8. Denis LJ, Griffiths K. Endocrine treatment in prostate cancer. Semin 
Surg Oncol. 2000;18(1):52–74.
 9. Bostwick DG. Prostatic intraepithelial neoplasia (PIN): current 
concepts. J Cell Biochem Suppl. 1992;16H:10–19.
10. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 
and ETS transcription factor genes in prostate cancer. Science. 
2005;310(5748):644–648.
11. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev 
Urol. 2009;6(8):429–439.
12. Han B, Mehra R, Dhanasekaran SM, et al. A fluorescence in situ 
hybridization screen for E26 transformation-specific aberrations: 
identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer 
Res. 2008;68(18):7629–7637.
13. Marx J. Medicine. Fused genes may help explain the origins of prostate 
cancer. Science. 2005;310(5748):603.
14. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of 
chromosomal rearrangements create oncogenic ETS gene fusions in 
prostate cancer. Nature. 2007;448(7153):595–599.
15. King JC, Xu J, Wongvipat J, et al. Cooperativity of TMPRSS2-ERG 
with PI3-kinase pathway activation in prostate oncogenesis. Nat 
Genet. 2009;41(5):524–526.
16. Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression 
cooperates with loss of PTEN to promote cancer progression in the 
prostate. Nat Genet. 2009;41(5):619–624.
17. Cerveira N, Ribeiro FR, Peixoto A, et al. TMPRSS2-ERG gene 
fusion causing ERG overexpression precedes chromosome copy 
number changes in prostate carcinomas and paired HGPIN lesions. 
Neoplasia. 2006;8(10):826–832.
18. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion 
associated with lethal prostate cancer in a watchful waiting cohort. 
Oncogene. 2007;26(31):4596–4599.
19. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/
ERG fusion messenger RNAs is associated with aggressive prostate 
cancer. Cancer Res. 2006;66(17):8347–8351.
20. Iljin K, Wolf M, Edgren H, et al. TMPRSS2 fusions with oncogenic 
ETS factors in prostate cancer involve unbalanced genomic rearrange-
ments and are associated with HDAC1 and epigenetic reprogramming. 
Cancer Res. 2006;66(21):10242–10246.
21. Lucas JM, True L, Hawley S, et al. The androgen-regulated type II 
serine protease TMPRSS2 is differentially expressed and mislocalized 
in prostate adenocarcinoma. J Pathol. 2008;215(2):118–125.
A C
B
C
C
F
F
R
R
C F R
Actin
tERG
GAPDH
AGT
0
1
2
3
4
5
6
Figure 5 eRg overexpression and regulation target gene expression. A) Total RnA 
was purified from transfected HeLa cells and cDNA was created. ERG target gene 
AgT was detected by RT-PcR. gAPDh was used as a loading control. B) Western 
blot to show the levels of the overexpressed truncated eRg.  Actin serves an internal 
control. C) histogram of the AgT expression regulated by eRg overexpression.  The 
intensities of the amplified band were quantified using Image-J software.  The mRNA 
levels were normalized with the internal control gAPDh. C: transfection without 
DnA; F: transfected with Forward clone; and R: transfected with reverse clone.
Pathology and Laboratory Medicine International 2009:1
Pathology and Laboratory Medicine International
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/pathology-and-laboratory-medicine-international-journal
Pathology and Laboratory Medicine International is a peer-reviewed, 
open access journal focusing on innovative basic research and 
translational research related to pathology or human disease. The 
journal includes original research, updates, case reports, reviews 
and commentaries on current controversies. The Academic Sponsor 
of this journal is the Chinese American Pathology Association 
(CAPA). The manuscript management system is completely 
online and includes a very quick and fair peer-review system. 
Visit http://www.dovepress.com/testimonials.php to read real quotes 
from published authors.
21
Truncated eRg and prostate cancerDovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
22. Vaarala MH, Porvari K, Kyllonen A, Lukkarinen O, Vihko P. The 
TMPRSS2 gene encoding transmembrane serine protease is over-
expressed in a majority of prostate cancer patients: detection of 
mutated TMPRSS2 form in a case of aggressive disease. Int J Cancer. 
2001;94(5):705–710.
23. Lin B, Ferguson C, White JT, et al. Prostate-localized and androgen-
regulated expression of the membrane-bound serine protease TMPRSS2. 
Cancer Res. 1999;59(17):4180–4184.
24. Agoulnik IU, Weigel NL. Androgen receptor action in hormone-
dependent and recurrent prostate cancer. J Cell Biochem. 2006;99(2): 
362–372.
25. Carver BS, Tran J, Chen Z, et al. ETS rearrangements and prostate 
cancer initiation. Nature. 2009;457(7231):E1; discussion E2–E3.
26. Wu S, Zhang Y. MUSTER: Improving protein sequence profile-
profile alignments by using multiple sources of structure information. 
Proteins. 2008;72(2):547–556.
27. Bateman A, Coin L, Durbin R, et al. The Pfam protein families 
database. Nucleic Acids Res. 2004;32(Database issue):D138–D141.
28. Oikawa T, Yamada T. Molecular biology of the Ets family of transcription 
factors. Gene. 2003;303:11–34.
29. Nasjetti A, Masson GM. Hepatic origin of renin substrate. Can J Physiol 
Pharmacol. 1971;49(10):931–932.
30. Tewksbury DA, Dart RA, Travis J. The amino terminal amino acid 
sequence of human angiotensinogen. Biochem Biophys Res Commun. 
1981;99(4):1311–1315.
31. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International 
union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol 
Rev. 2000;52(3):415–472.
32. Dinh DT, Frauman AG, Somers GR, et al. Evidence for activation 
of the renin-angiotensin system in the human prostate: increased 
angiotensin II and reduced AT(1) receptor expression in benign pros-
tatic hyperplasia. J Pathol. 2002;196(2):213–219.
33. Nassis L, Frauman AG, Ohishi M, et al. Localization of angiotensin-
converting enzyme in the human prostate: pathological expression in 
benign prostatic hyperplasia. J Pathol. 2001;195(5):571–579.
34. Uemura H, Ishiguro H, Nagashima Y, et al. Antiproliferative activity 
of angiotensin II receptor blocker through cross-talk between stromal 
and epithelial prostate cancer cells. Mol Cancer Ther. 2005;4(11): 
1699–1709.
35. Uemura H, Ishiguro H, Nakaigawa N, et al. Angiotensin II receptor 
blocker shows antiproliferative activity in prostate cancer cells: 
a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer 
Ther. 2003;2(11):1139–1147.
36. Uemura H, Ishiguro H, Ishiguro Y, Hoshino K, Takahashi S, Kubota Y. 
Angiotensin II induces oxidative stress in prostate cancer. Mol Cancer 
Res. 2008;6(2):250–258.
37. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 
420(6917):860–867.
38. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev 
Cancer. 2003;3(4):276–285.
39. Smith GR, Missailidis S. Cancer, inflammation and the AT1 and 
AT2 receptors. J Inflamm (Lond). 2004;1(1):3.
40. Lim SD, Sun C, Lambeth JD, et al. Increased Nox1 and hydrogen 
peroxide in prostate cancer. Prostate. 2005;62(2):200–207.
